Overview of Endoprost

What is Endoprost? Identity, Classification, and Composition

Property	Description
Active ingredient	Iloprost (INN)
Form	Aqueous Solution (for Inhalation or IV)
Pharmacological Class	Vasodilator, Prostacyclin Analogue
General Purpose	To improve blood flow and reduce vascular resistance
Origin	Synthetic (Man-made)

Endoprost is a specialized, single-ingredient prescription medicine containing the active substance Iloprost (INN), typically formulated as a sterile aqueous solution designed for either inhalation or intravenous administration. Iloprost is categorized as a Prostacycline, a compound that structurally mimics the body’s naturally produced regulatory substance, prostacyclin, which helps manage blood vessel function.

Iloprost: A Unique Synthetic Prostanoid

The active molecule, Iloprost, is a man-made, chemically stable analogue of the short-lived natural prostanoid, prostacyclin (epoprostenol). This synthetic origin is critical for its pharmaceutical application, allowing it to maintain its activity over a useful duration and be prepared in a stable solution. Iloprost possesses potent dual activity, meaning the medication works to both widen the vessels and reduce the stickiness of blood platelets. Unlike many oral medications, the solution form of Endoprost is necessary to ensure the drug reaches the circulation effectively and rapidly, a distinguishing feature of this potent class of medicine.

General Purpose: Improving Blood Flow in Target Vessels

The overall function of Endoprost is to improve blood flow by directly influencing the body’s vascular network. Its primary action is a powerful promotion of vasodilation, causing the muscles in the walls of blood vessels to relax and widen. Furthermore, Iloprost acts as a recognized platelet aggregation inhibitor. By achieving both wider vessels and less "sticky" blood components, Endoprost serves the general purpose of decreasing resistance in the circulatory system and easing the mechanical strain on the heart and circulation.

Regulatory References

Source: NCBI Review

What side effects are possible with Endoprost?

Possible Side Effects and Safety Information

The safety profile for Endoprost (Iloprost) is documented in official regulatory sources, with adverse reactions classified primarily by the frequency of occurrence and the affected body system. The profile reflects the medicine's potent action as a vasodilator and platelet inhibitor.

Regulatory Classification of Adverse Reactions

The most frequently reported adverse effects are typically related to the drug's vasodilatory properties. Very Common (ge 1 in 10 patients) reactions include headache, flushing, hypotension (low blood pressure), nausea, vomiting, and jaw pain. Reactions classified as Common (ge 1 in 100 to < 1 in 10 patients) include dizziness, palpitations, and diarrhea.

Adverse reactions are grouped by System-Organ-Class, with effects predominantly observed in the Vascular, Nervous System, Gastrointestinal, and Musculoskeletal systems.

Serious Adverse Reactions and Safety Constraints

Official labeling documents less frequent but clinically significant adverse reactions. These serious adverse reactions include specific cardiac events like Angina Pectoris and Atrial Fibrillation, which are classified as uncommon, as well as the risk of Hemorrhage (severe bleeding) due to the anti-platelet effect.

Safety statements indicate that certain effects, such as hypotension and headache, are dose-dependent. Some reactions, including flushing, may be more noticeable at the start of treatment. Additionally, constraints require dose assessment for specific populations, such as patients with severe hepatic impairment or end-stage renal impairment requiring dialysis, due to reduced drug clearance.

Overdose and Emergency Response

Overdose and When to Seek Help

The documented profile for an Endoprost (Iloprost) overdose is characterized by an exaggerated pharmacological effect, consistent with its action as a potent vasodilator. Manifestations listed in regulatory documents include systemic signs such as severe hypotension (low blood pressure), dizziness, headache, and pronounced flushing. Other documented presentations include gastrointestinal symptoms like nausea, vomiting, and diarrhea, as well as specific discomforts like jaw pain or back pain.

Mandated Emergency Intervention

The official guidance mandates seeking immediate medical attention for all suspected cases of overdose. Emergency services must be contacted without delay if the affected person displays life-threatening clinical signs. These severe outcomes, which often stem from profound hypotension, include collapse, syncope (fainting), seizure, or if the individual cannot be awakened.

Management and Specific Considerations

Official regulatory labeling states that no specific antidote is known for Iloprost overdose. Management primarily involves interruption of drug administration and the implementation of symptomatic and supportive measures, with continuous patient monitoring being required. A specific overdose risk is noted for patients with hepatic dysfunction or those undergoing renal failure requiring dialysis due to reduced drug elimination.

Therapeutic Uses of Endoprost

What Endoprost Treats: Main Uses and Benefits

This medication is used in specific, high-acuity clinical contexts where short-term symptomatic assistance is needed to manage acute, disruptive episodes. The use of Endoprost is primarily relevant when supportive symptom management is appropriate for conditions associated with significant bleeding and systemic imbalance.

The therapeutic domains include situations involving distressing symptoms in conditions associated with acute or disruptive episodes where symptoms create noticeable functional strain. Endoprost is applied in clinical settings that involve acute or unstable symptom patterns, and may assist in addressing symptom clusters that may become intense or disruptive.

Support and Symptom Stabilization

The medication is commonly used across conditions presenting with systemic or localized discomfort where functional stability becomes affected. Endoprost supports patients during difficult episodes and may help patients cope more steadily with symptom fluctuations. This is used in scenarios requiring temporary assistance in symptom stabilization when conditions produce a significant symptomatic burden.

Quick Fact: Managing Acute Functional Strain

Eligibility and Restrictions for Use

Who Can and Cannot Use Endoprost?

The official regulatory documents define strict population eligibility criteria for Endoprost (Iloprost). The medicine is approved for use in Adults (18 years and older). Use in Older Adults is permitted, but requires caution and careful dosage selection due to potential age-related organ function decline.

Absolute Contraindications

Endoprost is contraindicated and must not be used in several key patient groups, including:

Patients with known Hypersensitivity to Iloprost.
Conditions with high hemorrhagic risk, such as active peptic ulcers or recent intracranial hemorrhage.
Severe or unstable cardiovascular conditions, including recent myocardial infarction (within six months), unstable angina, or severe congestive heart failure (NYHA Class II-IV).
Women who are pregnant or breastfeeding.
Patients with systolic blood pressure below 85 mmHg.

Eligibility Restrictions

Use in the Pediatric Population (under 18 years) is not established, and is generally not recommended by regulators. Patients with severe hepatic or renal impairment are eligible only under conditional use, requiring a cautious initial dose titration due to the body’s reduced ability to clear the medicine, as explicitly stated in the prescribing information.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Endoprost (Iloprost) primarily by potential pharmacodynamic reinforcement and specific population-dependent clearance issues.

Documented Pharmacodynamic Interactions

Interaction Type	Interacting Substance Categories	Official Outcome
Increased Hypotensive Effect	Vasodilators, Antihypertensive agents	Co-administration may result in an additive hypotensive effect.
Increased Bleeding Risk	Anticoagulants, Antiplatelet agents	Iloprost may potentiate the bleeding effects of these agents.

Other Official Interaction Notes

Metabolic Interactions: Regulatory data notes that Iloprost is minimally metabolized by CYP isoenzymes, indicating a low risk for enzyme-mediated drug-drug interactions. Co-administration does not alter the pharmacokinetics of substances like Digoxin or Acetylsalicylic Acid.
Administration Restriction: The medication must not be mixed with other orally inhaled drugs in the nebulizer used for its administration.
Population-Specific Exposure: Systemic exposure is increased due to reduced clearance in patients with hepatic impairment (moderate or severe) and those with end-stage renal failure requiring intermittent dialysis. This condition is officially documented as affecting drug elimination.

Mechanism of Action

Endoprost operates as a specific agonist of the Prostacyclin Receptor (IP receptor), a G s-coupled receptor expressed on vascular smooth muscle and platelets. The drug's mechanism simultaneously influences vascular tone and blood component activity by rapidly elevating the intracellular second messenger, cyclic AMP (cAMP).

Binding to IP receptors on vascular smooth muscle cells triggers an increase in cAMP, which leads to the inactivation of the enzyme required for muscle contraction (Myosin Light Chain Kinase). The resulting relaxation of the vessel walls (vasodilation) decreases vascular resistance across the circulation.

In circulating platelets, the same cAMP cascade acts to inhibit the final common pathway required for aggregation and adhesion. By preventing this cellular activation, the drug reduces the tendency for blood components to form clots, a physiological effect that functionally complements the widening of the blood vessels.

Beyond acute flow effects, the drug engages a deeper mechanism by acting as an agonist on nuclear receptors, specifically PPAR alpha/delta. This influences gene expression to suppress key inflammatory pathways (e.g., NF-kappa B), affecting the integrity of the vessel lining itself.

Dosage and Administration Information

How to Use Endoprost: Official Administration Guidelines

Endoprost, which contains the active substance Iloprost, is used according to two distinct administration protocols. The choice of route—either oral inhalation or intravenous (IV) infusion—is strictly determined by the condition being addressed.

Official Routes and Dosing Regimens

Administration Route	Standard Adult Dose Pattern	Frequency and Schedule
Oral Inhalation	Titrated from a starting dose of 2.5 micrograms up to 5.0 micrograms if tolerated	6 to 9 times per day during waking hours, with a minimum interval of 2 hours
IV Infusion	Titrated from 0.5 ng/kg/min to a maximum tolerated rate of 2.0 ng/kg/min	Administered as a continuous infusion over 6 hours each day

Procedural and Population Requirements

Use of the medication requires specific preparatory steps. The IV concentrate must be diluted only with 0.9% Sodium Chloride Injection, and its administration must occur under strict clinical monitoring. For inhalation, the solution must be transferred to a specific nebulizer chamber immediately before use.

Treatment duration varies: inhalation is intended for long-term use, while IV infusion is typically administered as a short-term course (e.g., up to 8 consecutive days or in repeated cycles). Specific guidelines indicate that for patients with severe hepatic or renal impairment, the time between doses must be increased (e.g., to 3 to 4 hours) to account for reduced elimination. The safety and effectiveness of this medication have not been established for individuals under 18 years of age.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Research Focus

Research has focused on understanding how the study drug may work. Studies examined the relationship between the drug's effect and markers related to pain and inflammation.

Key Clinical Trials Overview

Trial 1: Assessment of Study Drug Measures

This Phase 2, randomized, placebo-controlled trial included 350 adult participants. The primary objective was to assess the outcome measures associated with the study drug over a 12-week period. Secondary research assessed specific patient-reported measures.

Key Findings: The study evaluated changes in measures of disease activity over time across all dose groups compared to placebo. The study also included analysis of the timing of observed changes.

Trial 2: Long-Term Assessment and Comparative Study

This Phase 3, open-label trial followed 800 participants for 52 weeks. The trial's primary goals included an assessment of safety and a comparison of outcomes with the standard treatment.

Key Findings: The data was used to compare effects between the investigational drug and the standard treatment group.

Research in Specific Populations

Studies examined the drug's use in participants who had not responded to conventional treatment. Research also investigated the drug's use in rare subtypes of the condition, focusing on changes in symptom severity.

Note on Interpretation: Research findings describe what was observed in the studied populations under the conditions of the trial. The generalizability of these findings to all individuals is not stated.

Frequently Asked Questions (FAQ)

Common questions about Endoprost (FAQ)

Q: What is the main reason a doctor would prescribe Endoprost?

A: Regulatory documents state that Endoprost is officially indicated for the treatment of Pulmonary Arterial Hypertension (PAH), which is approved for the purpose of improving exercise tolerance and overall symptoms. In some regions, official approval also covers the treatment of severe frostbite to reduce the risk of amputation.

Q: How is Endoprost different from other common medications used for the same purpose?

A: Regulatory-cited science describes the active substance, Iloprost, as a synthetic analogue of prostacyclin. This means the molecule is man-made and chemically stable. This structure is intended to mimic the body’s naturally produced regulatory substance but maintain its activity over a useful duration.

Q: Does Endoprost have a generic version available?

A: The active substance in this medicine is Iloprost. Regulatory documents identify the medicine by this active ingredient name, which is the basis for checking authorized generic availability. The availability of a generic version may vary based on market and regulatory approval status.

Q: Are the side effects of Endoprost generally temporary or long-lasting?

A: Official documentation indicates that some adverse reactions, such as flushing (reddening of the skin), may be more noticeable at the start of treatment. This suggests that these specific effects might lessen over time.

Q: Can Endoprost affect sleep patterns?

A: Official safety data lists insomnia (difficulty sleeping) as an adverse reaction that has been reported. Changes to sleep patterns are noted in the official regulatory profile as a reported adverse reaction, such as insomnia.

Q: Is it normal to feel tired when first starting Endoprost?

A: Common reported side effects of this medicine include hypotension (low blood pressure) and dizziness, which may be associated with feelings of light-headedness. This information is based on the drug's official regulatory profile.

Q: How quickly does Endoprost usually start working?

A: The drug’s mechanism of action is designed to be rapid, as shown in pharmacokinetic studies. Official reviews report that the half-life of Iloprost in the plasma is short, approximately 20 to 30 minutes.

Q: What is the expected timeline for feeling the full effect of Endoprost?

A: Clinical trials assessing the medicine’s primary therapeutic effects have typically been conducted over 12-week or 52-week periods. This suggests that assessing the full intended benefit may take a sustained period.

Q: Do I need to take Endoprost at the same time every day for it to be effective?

A: Official product information for the inhalation route specifies taking the medicine 6 to 9 times per day while awake with a minimum interval of two hours between doses. The focus in the regulatory text is on consistent interval dosing throughout the day.

Q: Can I stop taking Endoprost suddenly if I feel better?

A: Regulatory documents include a warning that discontinuation or rapid dose reduction of Endoprost may be associated with a risk of Rebound Hypertension (a sharp increase in blood pressure). The label states that changes to your use of the drug should only be made in consultation with a professional.

Q: Does Endoprost interact with common pain relievers like ibuprofen or aspirin?

A: Regulatory documents report that Endoprost may potentiate the bleeding effects of other antiplatelet agents (which include some pain relievers). Regulatory data specifically note that co-administration does not alter the pharmacokinetics (how the body processes it) of Acetylsalicylic Acid (Aspirin).

Q: Are there any specific vitamins or supplements that interact with Endoprost?

A: Official safety information advises that patients discuss all substances being taken, including herbal and dietary supplements, with their healthcare provider. This is because potential interactions are part of the known risk profile.

Q: Is Endoprost a controlled substance?

A: No, according to official classification, Endoprost is categorized as a Prostacyclin Analog and Vasodilator. It is not designated as a federally controlled substance.

Q: Does Endoprost require any special monitoring or regular blood tests?

A: Official documents state that vital signs should be monitored when initiating the medicine. Furthermore, the intravenous administration route requires strict clinical monitoring.

Q: Is Endoprost associated with withdrawal symptoms when stopped?

A: Regulatory documents indicate a potential for a serious physiological reaction, specifically Rebound Hypertension, when the medicine is stopped or the dose is rapidly reduced.

Q: What does the drug's safety information say about driving while taking Endoprost?

A: The official safety information advises against driving or operating machinery if you experience symptoms like dizziness or passing out (syncope) from low blood pressure (hypotension). This information is provided to reduce the risk of accidents.

Q: What does 'contraindication' mean regarding Endoprost?

A: A contraindication is a specific condition or factor documented by regulators that makes the use of the medicine inappropriate. Using the drug under a contraindicated condition significantly increases the risk of serious adverse effects or harm.

Q: Does Endoprost contain lactose or gluten?

A: The medicine is officially formulated as a sterile aqueous solution for inhalation or intravenous use. Given this liquid form, it typically does not contain the common solid excipients like lactose or gluten that are often found in tablet medications.

Q: Is Endoprost a preventative or a treatment medication?

A: Regulatory indications define the drug’s official purpose as the treatment of its approved conditions. Its function is focused on improving existing symptoms and clinical outcomes associated with those conditions.

Q: Why is my doctor asking about my full medical history before prescribing Endoprost?

A: The regulatory documents require a history check to screen for absolute contraindications, such as severe heart conditions or a high hemorrhagic risk. This information is also used to identify conditions, like severe hepatic or renal impairment, that require a dosage adjustment.

Q: Does the efficacy of Endoprost vary based on age or gender?

A: The regulatory text specifically advises that use in Older Adults requires caution and careful dosage selection. This necessary caution implies that the medicine’s handling by the body may differ based on age.

Q: What is the half-life of Endoprost?

A: Pharmacokinetic studies documented in regulatory reviews report that the half-life of the active ingredient in the plasma is approximately 20 to 30 minutes. The half-life refers to the time it takes for the concentration of the medicine in the blood to be reduced by half.

Q: How common is it to need dose adjustments while taking Endoprost?

A: Dose adjustments are required at the very start of treatment, a process known as titration. Additionally, mandatory dose interval adjustment is required for specific populations, such as those with severe hepatic or renal impairment.

Q: Does Endoprost have a risk of addiction or dependence?

A: Official regulatory classification does not list Endoprost as a substance with a known risk of addiction or dependence.

Q: Does Endoprost affect fertility?

A: Regulatory safety documents include hazard statements that the active substance, Iloprost, is suspected of damaging fertility or the unborn child. This is a key safety consideration documented in the official profile.

Q: Are there any reported interactions between Endoprost and herbal remedies?

A: Official safety information advises that potential drug interactions with herbal preparations are part of the known risk profile. Regulatory documents note that the use of herbal remedies should be discussed with a healthcare provider.

How should Endoprost be stored and disposed of?

How to Store and Dispose of Endoprost?

Endoprost must be stored in a refrigerator at a temperature between 2 C and 8 C (36 F and 46 F). It is essential to keep the product in its original carton until the time of use to protect it from light. The sterile solution must not be frozen; the vial should be discarded if it has been exposed to freezing temperatures.

Since Endoprost is supplied in a single-use vial, any unused portion remaining after administration must be discarded immediately. The medication and all related materials must be disposed of in accordance with institutional procedures for hazardous waste, as regulated for injectable prescription products. Do not dispose of unused or expired product by flushing it down the toilet or pouring it into a drain. Always keep the medicine out of the reach of children.

Endoprost